Skip to content

Multiple sclerosis

The guideline here is NICE NG220 (2022, amended 2026), which covers diagnosis, symptom management, relapse and disease-modifying therapy for adults. Diagnosis now follows the 2024 revised McDonald criteria.

NICE NG220 2022

International Current

Multiple sclerosis in adults: management (NG220)

Official source

Clinical pearls

  • Relapse: >24 h, ≥30 days after the last one, no infection or fever. Methylprednisolone 0.5 g oral for 5 days (or 1 g IV for 3–5 days).
  • Spasticity: baclofen, then gabapentin. Oscillopsia: gabapentin, then memantine.
  • Primary progressive MS: ocrelizumab. Active secondary progressive: siponimod.